Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 10.46
- Piotroski Score 8.00
- Grade Buy
- Symbol (EXEL)
- Company Exelixis, Inc.
- Price $34.84
- Changes Percentage (0.55%)
- Change $0.19
- Day Low $34.40
- Day High $35.00
- Year High $36.60
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/04/2025
- Fiscal Year End N/A
- Average Stock Price Target $30.00
- High Stock Price Target $38.00
- Low Stock Price Target $18.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.65
- Trailing P/E Ratio 33.66
- Forward P/E Ratio 33.66
- P/E Growth 33.66
- Net Income $207.77 M
Income Statement
Quarterly
Annual
Latest News of EXEL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Drexel University's hockey and basketball teams form an unbreakable bond: "We're all just Dragons for life"
The Drexel club hockey team and men's basketball team support each other, creating a strong bond. The basketball coach showed gratitude by attending the hockey game, fostering a culture of unity and s...
By CBS News | 2 days ago -
Fairfield hosts Drexel following Johnson's 25-point game
Fairfield will play against Drexel after a strong performance by Prophet Johnson, leading Fairfield to a 93-44 win over John Jay. Both teams had solid records last season, with Fairfield shooting well...
By AP NEWS | 3 days ago -
Exelon Corporation's (NASDAQ:EXC) Intrinsic Value Is Potentially 29% Above Its Share Price
Exelon Corporation (EXC) is currently undervalued by 23% according to analysts' price target of US$43.02. Using a Discounted Cash Flow (DCF) model, the intrinsic value calculation suggests a fair valu...
By Yahoo! Finance | 4 days ago
